Affecting roughly half a million Americans each year, bacterial infections caused by Clostridioides difficile - commonly known as C. diff - are a serious and persistent problem for patients and ...
Acurx's Program in the Broader CDI Patient Population is Ready to Advance toPhase 3 International Clinical Trials Acurx previously announced that it had received positive regulatory guidance from the ...
There are about half a million C. diff infections every year in the United States. About 30,000 people die from them annually. But if you’ve had C. diff, you’re more likely to get it again. About 1 in ...
Affecting roughly half a million Americans each year, bacterial infections caused by Clostridioides difficile—commonly known as C. diff—are a serious and persistent problem for patients and hospitals ...
A novel vaccination approach developed by Vanderbilt Health researchers cleared the harmful gut bacterium Clostridioides difficile (C. diff) in an animal model of infection. An experimental vaccine ...
DEAR DR. ROACH: I am a 76-year-old male who is in relatively good health. For the past six months, I have been experiencing diarrhea on and off. I initially spoke to my general physician, and he ...
STATEN ISLAND, N.Y., March 9, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (Nasdaq: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results